AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 152 min read$CHRN

ChronoScale (CHRN) Q1 Revenue $41.5M, Up 148% YoY; Net Loss $26.4M

ChronoScale reported Q1 2027 revenue of $41.5M, up 148% YoY, and a net loss of $26.4M. Adjusted EBITDA was $5.9M, down from $9.4M a year ago. The company had $15.2M in cash. The Legacy Ekso Business sale closed in September 2026.

Original reporting
tradingview.com
Published Oct 15, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ChronoScale (CHRN) Q1 Revenue $41.5M, Up 148% YoY; Net Loss $26.4M — source image
Source · tradingview.com
Decision brief

The 30-second read

$CHRNNeutralMed
01

Why it matters

Traders will likely focus on whether adjusted EBITDA improvement ($5.9M vs $9.4M) and cash ($15.2M) indicate improving operating leverage or rising financing risk, especially with the stated $1B ARR run-rate goal by Q3 2027.

02

Market read

A newly reported quarterly print with hard numbers (revenue, net loss, adjusted EBITDA, cash) provides a direct basis for repricing CHRN’s growth versus financing-risk profile.

03

What to watch

The Legacy Ekso Business sale closing Sept. 30, 2026 may change segment economics; traders may need to separate continuing-operations performance from legacy effects.

Relevance 8/10Novelty 8/10Timing: post-market today, based on the newly reported Q1 2027 results

Background

The piece frames CHRN as an early-stage build-out after a business pivot, with rapid revenue growth but negative GAAP earnings.

Company-level read

Ticker impact

$CHRNNeutralMedium confidence
Context

ChronoScale (CHRN) reported fiscal Q1 2027 revenue of $41.5M (+148% YoY) alongside a $26.4M net loss and $15.2M cash.

Expected impact

Likely mixed reaction, with upside from rapid revenue growth tempered by concern over ongoing losses and cash burn.

Evidence & confidence

The article provides the quarter’s revenue, net loss, adjusted EBITDA, and cash balance, which typically drive valuation and financing-risk repricing for early-stage issuers.

Market effects

Sector

Signals ongoing volatility for early-stage healthcare/tech-like growth companies where revenue growth can outpace profitability.

Regional

No clear regional spillover indicated beyond small-cap risk appetite.

Global

Limited, company-specific earnings-style disclosure with no stated cross-border catalyst.

Counterpoint

What could challenge this read

The revenue surge could be driven by one-time factors or deployment timing, so investors may discount it until margins and cash conversion improve.

Key entities

  • company
    ChronoScale Holdings Corporation

    Reports Q1 2027 revenue, losses, adjusted EBITDA, cash, and notes the Legacy Ekso Business sale closing Sept. 30, 2026.

Read at source← All news

Related articles

OCT 15
$CHRNMedAI 8/10

ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. – October 15, 2026 — ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence

SEC EDGAR 8-K6 min
OCT 2
$CHRNMed

ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

ChronoScale Holdings (CHRN) shares rose after expanding AI infrastructure contracts, projecting a $1 billion annualized revenue run rate by Q3 2027. The company also completed the sale of its Ekso Bionics business. CHRN is trading at $20.33, above its 20-day and 100-day SMAs but below the 50-day SMA. Analysts rate CHRN as Strong Buy with an average price target of $32.

aol.com2 min
OCT 1
$CHRNHighAI 8/10

ChronoScale stock jumps on $1B revenue target from AI deals

ChronoScale Corp (CHRN) shares rose 3% after-hours after announcing deals expected to reach $1B annualized revenue run rate by Q3 2027. The AI infrastructure provider signed a contract extension and new customer agreement, though revenue is subject to deployment and capital risks. The company also sold its Ekso Bionics unit to focus on core AI infrastructure business.

investing.com1 min